Compare Enveric Biosciences Inc (ENVB) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wynn Resorts, Limited — how do they compare? Enveric Biosciences Inc trades at $1.58 (market cap $6.20M), while Wynn Resorts, Limited trades at $104.52 (market cap $10.79B). The key difference: Wynn Resorts, Limited is far larger — about 1740.3× Enveric Biosciences Inc's market cap, and Wynn Resorts, Limited pays a 0.95% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | WYNN | |
|---|---|---|
Market Cap | $6.20M | $10.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $133.34 |
52-Week Low | $1.27 | $94.37 |
Enterprise Value | $1.30M | $21.03B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
Wynn Resorts (WYNN) trades at $104.59, up 2.04% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, driven by Macau performance, though U.S. margins face pressure. The company maintains solid revenue growth but carries high debt levels, with net cash flow negative due to significant capital expenditures for expansion projects like Wynn Al Marjan.
The outlook is cautiously optimistic, with a consensus price target of $133 offering ~27% upside. Key opportunities include Macau recovery and new project growth, while risks involve high leverage, rising capex, and regional economic sensitivity. Investors should weigh strong institutional support against execution risks in upcoming expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
